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Abstract
The present study aimed to use QuantiFERON TB Gold in tube
(Cellestis Limited, Carnegie, Victoria, Australia) as a tool for the
screening for tubercular infection in HIV-positive patients. Sev-
enty-three HIV-positive subjects were tested. For each individ-
ual, QuantiFERON TB in tube was performed. The immunoassay
was negative in 53 subjects, positive in eight and indeterminate
in 12. The data obtained indicate that factors such as the CD4
cell count and their percentage, as well as the stage of the dis-
ease, could affect the performance of the interferon-c release
assay in populations at risk such as HIV-positive subjects.
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In HIV-positive subjects, a precise diagnosis of latent tuber-
cular infection (LTBI) is very important, although the tuber-
culin sensitivity Test (TST), the tool for this diagnosis, has
reduced sensitivity after the anergy as a result of their state
of immune suppression [1].
QuantiFERON TB Gold in tube (QFT-IT) (Cellestis Limited,
Carnegie, Victoria, Australia) is a test based on the release of
interferon-c after stimulation of T cells with antigens ESAT-6,
CFP-10 and TB7.7 speciﬁc for Mycobacterium tuberculosis
complex [2]. Its sensitivity and speciﬁcity has been evaluated
extensively in immunocompetent patients [3–8], although
there is little information regarding its applicability in HIV
individuals, in whom the immune-suppression might affect the
performance of the.QFT-IT.
In patients with active TB-HIV co-infection, QFT-IT and
TST show same sensitivity and, in subjects with low CD4 cell
count, can both give false-negative results [9].
The present study aimed to use QFT-IT as a tool for the
screening for tuberculosis (TB) infection in HIV-positive
patients and to evaluate whether factors such as CD4 cell
count and percentage, as well as viral load, could inﬂuence
its outcome.
QFT-IT was carried in 73 patients hospitalized at the
Clinic of Infectious Diseases, University of Sassari (Sassari,
Italy). All subjects provided their consent prior to screening
procedures.
Patients characteristics and clinical data were collected
(Table 1).
TST was performed on the day of hospital discharge of
patients.
QFT-IT was performed in the Laboratory of Mycobacteri-
ology (University of Sassari), in accordance with the manufac-
turer’s instructions.
The statistical analysis was performed using STATISTICA, ver-
sion 6.0 (StatSoft, Inc., Tulsa, OK, USA). One-way analysis of
variance was used and a post-hoc comparison was per-
formed using the Newman–Keuls test. p <0.05 was consid-
ered statistically signiﬁcant.
TST results were available only in 13% of patients and,
consequently, it was not possible compare the results with
the QFT-IT (data not shown).
QFT-IT was positive in eight subjects. They had a mean
CD4 cell count of 317 ± 153 cells/lL, an average %CD4 of
17 ± 8% and a median viral load of 210 000 ± 207 000 cop-
ies/mL (Table 2). Two positive QFT-IT patients had active
TB (both were in the stage C3). Six had other diseases
(gastropathy, neuropathy, pneumonia aspergillosis) and, as
determined by QFT-IT, they also had a LTBI.
Thirty-two patients with CD4 cell count >200 cells/lL
had negative QFT-IT with a mean of CD4 cell count of
410 ± 178 cells/lL, a mean %CD4 of 25 ± 7 and a mean viral
load of 306 000 ± 660 000 copies/mL. The other 21 sub-
jects, with a CD4 cell count <200 cells/lL, had negative
QFT-IT with a mean CD4 cell count of 92 ± 60 cells/lL, a
mean %CD4 of 8 ± 5 and a mean viral load of
269 000 ± 340 000 copies/mL (Table 2).
Among all the subjects with negative QFT-IT, six had
active TB and all were in stage C3. Twelve patients had inde-
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terminate QFT-IT and an average CD4 cell count of
177 ± 215 cells/lL, a mean %CD4 of 9 ± 7 and a median
viral load of 346 000 ± 504 000 copies/mL (Table 2). One of
these patients had active TB and was in stage C.
All patients with active TB received anti-TB therapy.
Seventeen (23%) patients were on highly-active antiretro-
viral therapy (HAART); 13 of these (76.4%) were receiving
protease inhibitors, one was receiving efavirenz, one was
receiving raltegravir and two were receiving nucleoside
reverse transcriptase inhibitors.
HAART and opportunistic infections did not affect the
results of the QFT-IT (data not shown).
A signiﬁcant statistical difference in the mean CD4 cell
count and percentage was observed among subjects with
positive and indeterminate QFT-IT (p 0.022, p 0.006);
patients with positive and negative QFT-IT (CD4 cell counts
<200 cells/lL) (p 0.007, p 0.001); subjects with CD4
>200 cells/lL and CD4 <200 cells/lL with negative QFT-IT
(p 0.0001, p 0.0001); and among subjects with negative
QFT-IT (CD4 >200 cells/lL) and indeterminate immunoassay
(p 0.0001, p 0.0007).
No difference was observed in none of these patients for
the median viral load (p 0.24, p 0.49, p 0.7).
In the subjects with negative QFT-IT (CD4 cell count
<200 cells/lL), there was no statistical difference compared
to patients with indeterminate QFT-IT with respect to the
mean count and %CD4 (p 0.160, p 0.758) and viral load
(p 0.101).
Among positive QFT-IT and negative QFT-IT subjects
(CD4 cell count >200 cells/lL), there was no signiﬁcant dif-
ference between the average CD4 cell count and viral load
(p 0.182, p 0.98), although a difference was observed for
median %CD4 (p 0.007).
CD4 cells are fundamental in the production of antigen
speciﬁc interferon-c; thus, in HIV patients, the result of the
QFT-IT may be inﬂuenced by the absolute count of these
cells.
The results obtained in the present study show that, in
patients with a positive immunoassay and in subjects with
negative QFT-IT (CD4 cell count >200 cells/lL), the mean
count and percentage of lymphocytes was almost two-fold
greater than that recorded in patients with indeterminate
QFT-IT or in negative QFT-IT subjects (CD4 cell count
<200 cells/lL). This indicates that these factors could inﬂu-
ence the outcome of QFT-IT and should be considered
when this assay is prescribed.
We observed that the mean cell counts and %CD4 in neg-
ative QFT-IT subjects (CD4 cell count <200 cells/lL) and
indeterminate immunoassay are very close.
TABLE 1. Characteristics of the study population
Patient characteristic Number and percentages
Age (years) 41 (21–63)
Sex
Female 23 (31%)
Male 50 (69%)
Race
Italian 68 (93%)
African 5 (7%)
HIV history
CD4 cell count, mean (range) 270 cells/lL (4–897 cells/lL)
%CD4, mean (range) 16.21% (0.6–37%)
HIV viral load, mean (range) 576.000 (<40–15 000 000
copies/mL)
Patients on HAART 17 (23%)
CDC stage of infectiona 9 A1-A2-A3 (12%)
26 B1-B2-B3 (36%)
38 C1-C2-C3 (52%)
History of opportunistic infection 18 (25%)
TB history
Active TB 9 (12%)
Contact 1 (1.3%)
Risk factor
Homosexuals 8 (11%)
Intravenous drug use 44 (60%)
QFT-IT results
QFT-IT negative 53b (73%)
QFT-IT positive 8c (11%)
QFT-IT indeterminate 12d (16%)
aCDC stage A includes: asymptomatic HIV infection, persistent generalized
lymphadenopathy or primary HIV infection; CDC stage B consists of symptom-
atic HIV infection. CDC Stage C is characterized by a diagnosis of AIDS deﬁning
conditions.
bThirty-two subjects with CD4 cell counts >200 cells/lL, three of them with
active tuberculosis (TB) (three cases of lymph node TB), and 21 subjects with
CD4 cell counts <200 cells/lL, three of them with active TB (two cases of
pulmonary, one case of disseminated TB).
cTwo with active TB (military TB and brain).
dOne with active miliary TB.
HAART, highly-active antiretroviral therapy; QFT-IT, QuantiFERON TB Gold in
tube.
TABLE 2. QFT-IT results, CD4, %CD4 and HIV viral load
QFT-IT results
Negative with CD4
>200 cells/lL
Negative with CD4
<200 cells/lL Positive Indeterminate
Mean CD4 cell count cells/lL 410 ± 178 92 ± 60 317 ± 53 177 ± 215
Mean % CD4 25 ± 7 8 ± 5 17 ± 8 9 ± 7
Mean HIV viral load copies/mL 306 000 ± 660 000 269 000 ± 340 000 210 000 ± 207 000 346 000 ± 504 000
Data are expressed as the mean ± SD.
QFT-IT, QuantiFERON TB Gold in tube.
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This indicates that, in patients with a low lymphocyte
count, the immunoassay could have a low sensitivity and give
false-negative results. Indeed, three negative QFT-IT subjects
had active TB with a CD4 cell count of 17, 95 and 19 cells/
lL, respectively.
Among QFT-IT negative subjects (CD4 cell count
>200 cells/lL), three had active TB, their CD4 cell count
was >400 cells/lL, and the percentage of lymphocytes in two
cases was >15%, whereas, in one patient, it was 10%. Thus,
it is very important to assess not only CD4 cell counts, but
also their percentage in the total population because a low
percentage may lead to false-negative results. In the two sub-
jects with a high count and a high percentage of lympho-
cytes, the negative QFT-IT response may not be a result of
HIV but, instead, active TB; several studies have been shown
that, in immunocompetent individuals with active TB, QFT-IT
has a low sensitivity [10].
Patients with active TB and negative QFT-IT (both CD4<
and >200 cells/lL) were in stage C3 of HIV infection, and
this factor may have led to the failure of the immunological
assay. As HIV infection progresses, there is a switch from
the cellular to the humoural immune response with a reduc-
tion in the production of interferon-c [11].
A limitation of the present study is the limited number
of subjects with active TB who were tested, although our
ﬁndings conﬁrm the previously published data [9]. The
results obtained in the present study indicate that the inter-
feron-c assay was affected by the CD4 cell count and per-
centage, as well as by the stage of HIV infection. It would
be very useful to establish threshold values with regard to
the CD4 parametres below which the immunoassay may
not be sensitive and give false-negative or indeterminate
results.
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Abstract
The present study was conducted to survey the prevalence and
genotypic distribution of human astrovirus (HAstV) circulating in
South Korea. Of 160,027 patients with acute gastroenteritis,
2,057 (1.3%) were positive for HAstV antigen. We determined
the genotypes of 187 HAstV strains collected from laboratories
across the country. Genetic analysis revealed genotype 1 to be
the most prevalent, accounting for 72.19% of the strains, fol-
lowed by genotypes 8 (9.63%), 6 (6.95%), 4 (6.42%), 2 (3.21%)
and 3 (1.60%). Our ﬁndings indicate that HAstV is less common
but, even so, a potentially important viral agent of gastroenteritis
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